About this Research Topic
Tuberculosis (TB), is one of the leading causes of death due to an infectious disease agent. The morbidity and mortality caused by TB are enhanced by immune-compromising conditions, such as coinfection with HIV, co-morbidities like diabetes, malnutrition, malaria and the emergence of drug resistant Mtb strains.
TB is both a preventable and fully curable disease. Currently recommended curative therapy for drug-susceptible TB comprises of a 6–9 months regimen of four first line drugs: isoniazid, rifampicin, ethambutol, and pyrazinamide. However, patient compliance decreases over time due to adverse side effects, drug fatigue, disappearance of symptoms and return to near normal state, leading to infrequent intake and discontinuation of the regimen. This has contributed to the emergence of multi-drug resistant TB, which is a major challenge to global public health.
Attempts to further shorten the duration of treatment with the existing drugs has not given satisfactory results so far. Moreover, all new regimens to shorten the duration of treatment have focused only on the bug. Mycobacterium tuberculosis also has a property to escape killing by the anti-TB drugs and become persistent in the host, even though it is sensitive to the anti-TB drugs. It escapes the immune mechanism of the host.
So while strengthening the attack on the bug, one should also concentrate to increase the host response against the bug. Host directed therapy (HDT) could be an attractive additive approach to restore or to enhance host immunity. The aim would be to maximize bacterial killing, while minimizing inflammatory tissue damage together with conventional anti-TB drugs. These agents are not microbicidal per se, but can modulate host immunity, combating M.tb and may enhance the activity of the anti-TB drugs.
The goal of this collection is to review and analyze the various recent advances in the field of Host-directed therapies for the management of Tuberculosis
This Research Topic will consider various article types, including, randomised clinical trials, review articles and meta analysis.
Themes of particular interest are:
Clinical patient management - Phase II & III trials
Laboratory studies - Early bactricidal studies and Phase I trial
Laboratory studies - In vitro studies and Pre-clinical studies
Keywords: Host-directed, Autophagy, Repurposed drugs, Anti-TB treatment, Novel mechanism
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.